Immunological relationship between autoimmune liver disease and autoimmune thyroid disease: a cross-sectional study

Qingmin Zeng
Tianjin Medical University

Min Gao
Tianjin Second people's Hospital

Chunyan Wang
Tianjin Second People's Hospital

Xu Han
Tianjin Second People's Hospital

Chen Chen
Tianjin Second People's Hospital

Lili Zhao
Tianjin Second People's Hospital

Chunhua Tu
Tianjin Medical University

Ping Han
Tianjin Second People's Hospital

Jia Li
Tianjin Second People's Hospital

18622663700@163.com Corresponding Author

DOI:
10.21203/rs.2.10477/v1

SUBJECT AREAS
Immunology Allergy & Immune Disorders

KEYWORDS
Liver disease, Thyroid disease, Autoimmune; Immunological relationship; Retrospective study
Abstract
Background: High prevalence of autoimmune thyroid disease (AITD) in patients with autoimmune liver disease (AILD) has been observed. Data on the clinical relationship between AILD and AITD remain scanty. We aimed to evaluate the immunological relationship between AILD and AITD. Results: 324 patients with AILD were enrolled, 113 out of 324 patients were concurrent AITD (34.9%). Patients with autoimmune hepatitis (AIH) were more likely to develop AITD (45.8%), followed by autoimmune hepatitis-primary biliary cholangitis overlap syndrome (AIH-PBC OS) (39.5%) and PBC (22.6%). AILD patients with concurrent AITD showed higher levels of IgG (21.5 g/L vs 16.3 g/L, P<0.0001) and gamma globulin (γ-globulin) (27.1% vs 21.9%, P<0.0001), and IgG were positively correlated with thyroid antibodies thymoglobulin antibody (TGAb), thyroid peroxidase antibody (TPOAb) (r=0.396, 0.322; P<0.0001, P=0.002, respectively). The frequency of TPOAb positivity was highest in PBC patients with concurrent AITD (83.9%). The AIH concomitant with AITD had a higher nuclear homogenizing antinuclear antibody (ANA) positivity compared with the AIH alone (P=0.019). PBC patients with concurrent AITD were significantly older than the PBC patients without AITD (P=0.0004). Thyroid dysfunction in AILD patients with concurrent AITD was principally characterized by Hashimoto's thyroiditis (65.5%) and diffuse lesions were mainly indicated in thyroid ultrasound (53.1%). Conclusions: The high incidence of AILD concomitant with AITD, as well as the higher levels of serum IgG and γ-globulin, and the strong correlation between thyroid antibody and IgG, suggesting that we should strengthen the screening of autoimmune thyroid disease when diagnosing and treating autoimmune liver disease.

Background
Autoimmune liver disease (AILD), caused by the imbalance of immune tolerance and leading to liver and gallbladder system damage, is a group of autoimmune diseases. The spectrum of AILD includes autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndrome (OS). Autoimmune thyroid diseases (AITD), featured by the production of autoantibody which induced by abnormal autoimmune responses and targets thyroid cells, is a class of organ-specific autoimmune disease, and mainly including Hashimoto's thyroiditis (HT) and Graves'
disease (GD). AILD frequently overlap other extrahepatic autoimmune disease (EHAID) [1-3], AITD is the commonest concurrent EHAID in AILD patients (10-23%) [4-6]. The high incidence of AILD concomitant with AITD may be closely relevant to its underlying pathogenesis. Dr. Daya CM [7] proposed the concept of molecular mimicry, that is, infection with a virus or bacterium that contains a protein similar to a thyroid protein may result in the activation of thyroid-specific T cells, triggering immune system disorders and giving rise to thyroid dysfunction. Whether hepatocytes or cholangiocytes and thyroid cell have similar proteins, which cross-react with each other and activate specific T cells, leading to the concurrence of AILD and AITD, remains yet to be determined.

The incidence rate, clinical features, and outcomes in AILD patients concomitant with EHAID have been analyzed by previous studies [8-15]. No targeted study on the correlation between AITD and AILD has been conducted. Therefore, our study intends to analyze the differences in biochemical and immunological indicators between AILD patients with and without AITD and to explore the possible association of clinical immunology between the two diseases.

Methods

Patient selection

Retrospectively recruited 324 inpatients with AILD at Department of Hepatology, Tianjin Second People's Hospital, Tianjin, between January 2013 and January 2019. 113 out of 324 were concurrent autoimmune thyroid disease. This study was approved by the Ethics Committee of Tianjin Second People's Hospital and all subjects have given informed.

The diagnosis of AIH was made based on the revised IAIHG scoring system issued in 1999 by the International Autoimmune Hepatitis Group [16]. The diagnosis of PBC was made based on the European Association for the Study of the Liver (EASL) PBC Clinical Practice Guidelines (2017) [17]. The diagnosis of PSC was made based on the consensus of experts in the diagnosis and treatment of primary sclerosing cholangitis (2015) [18]. The diagnosis of AIH-PBC OS was made based on EASL Clinical Practice Guidelines for the management of cholestatic liver disease (2009) [19]. Viral hepatitis, non-hepatotrophic virus infection, alcoholic liver disease, drug-induced hepatitis, and hereditary metabolic liver disease were excluded.
Associated diagnosis of EHAID and family history of autoimmune diseases were searched and retrieved via the hospital electronic records, clinical letters and medical case notes. All these diseases have been diagnosed and confirmed based on the international criteria. The diagnosis of GD was based on the American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) [20]. The diagnosis of HT was based on the Chinese Guidelines for diagnosis and treatment of Adult Hypothyroidism (2017) [21].

**Laboratory methods**

Patients’ case records, such as age, sex, symptoms, personal and family history, were systematically reviewed and examined. Clinical liver enzymes like serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and immunological indicators like immunoglobulin G (IgG), immunoglobulin M (IgM), gamma globulin (γ-globulin) were measured by Turbidimetric inhibition immunoassay (Hitachi 7180 Automatic Biochemical Analyzer). Antinuclear antibody (ANA), anti-mitochondrial antibody (AMA), anti-smooth muscle antibody (ASMA), anti-mitochondrial antibody M2 (AMA-M2), anti-dsDNA antibody and anti-centromere antibody were analyzed by indirect immunofluorescence or immunoblotting (Cycleblot 48 Automatic Western blotting).

Total triiodothyronine (TT3), total thyroid hormone (TT4), free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), thyroglobulin antibody(TGAb) and thyroid peroxidase antibody (TPOAb) were detected with electro-chemiluminescence (Roche cobas e 411 Analyzer, Switzerland).

Thyroid ultrasounds were performed by a well-trained physician (PHILIPS U22, Netherlands).

A liver biopsy was performed in 187 patients with AILD. Histological assessment of the severity of liver inflammation and the degree of fibrosis was based on the scoring system proposed by Batts and Ludwig [22]. Biopsies were evaluated by two experienced pathologists that were unaware of the subjects’ identity or clinical information.

**Statistical analysis**

Results were analyzed using SPSS version 23.0 (IBM Corp, USA). Continuous variables satisfied
normality were expressed as mean±standard deviation (x±SD), and Student t-test was used to compare the differences in variable between the two groups. Non-normal continuous variables were expressed as median and inter-quartile range [M(P25~P75)], and Mann-Whitney test was applied. Categorical variables are expressed as actual numbers and percentages. Group comparisons of variables were analyzed with \( \chi^2 \)-test or Fisher’s exact test if the expected cell frequency is <5. Bivariate Spearman correlation test was used to analyze the correlation of two pair random variables. P<0.05 was considered significant.

Results

**Sociodemographic and biochemical indicators**

Among the 324 patients with AILD, AIH, 142 (43.8%) patients; PBC, 137 (42.3%) patients; PSC, 2 (0.6%) patients; AIH-PBC OS, 43 (13.3%) patients. AITD was the commonest EHAID in AILD patients (34.9%) (Table 1).

Patients with AIH were more likely to develop AITD (45.8%), followed by AIH-PBC OS (39.5%) and PBC (22.6%). (Figure 1)

There were no significant differences in sex and biochemical parameters such as liver enzymes (ALT, AST, GGT, ALP) between AILD patients with and without AITD (P>0.05). PBC patients with concurrent AITD were significantly older than the PBC patients without AITD (P=0.0004). (Table 2, Table 3, Table 4)

**Immunological indicators**

AILD patients with concurrent AITD showed higher levels of IgG (21.5 g/L vs 16.3 g/L, P<0.0001) and γ-globulin (27.1% vs 21.9%, P<0.0001). (Table 5)

The serum IgG levels in the three subgroups of AILD patients with concurrent AITD was higher than those of patients without concurrent AITD (21.7g/L vs 17.5g/L, P<0.0001; 20.3g/L vs 15.4g/L, P<0.0001;24.3g/L vs 18.6g/L, P=0.035, respectively). The serum γ-globulin levels were noticed significantly different between AIH or PBC patients with and without AITD (26.4% vs 22.4%, P<0.0001; 26.7% vs 21.3%, P=0.0004, respectively); no differences emerged between AIH-PBC OS with and without AITD (P=0.081). (Table 2, Table 3, Table 4)
Significant correlation exists between IgG and TGAb or TPOAb in AILD patients with concurrent AITD ($r=0.396, 0.322; P<0.0001, P=0.002$, respectively). (Table 6)

**Autoantibody profile**

No significant differences were observed in ANA between PBC/AIH-PBC OS patients with and without AITD ($P>0.05$) (Table 3, Table 4). But the nuclear homogenous ANA between AIH patients with and without AITD was excluded ($P=0.019$). (Table 2)

**Thyroid function**

Thyroid dysfunction were mainly manifest as Hashimoto's thyroiditis and thyroid antibody positivity in AILD concomitant with AITD, and ultrasound indicated diffuse thyroid lesions. The frequency of TPOAb positivity differed significantly among the three subgroups of AILD concomitant with AITD ($P=0.035$), especially the highest positivity in the PBC concomitant with AITD. And AITD more frequently coincided with or posterior to AILD’s onset. (Table 7)

**Discussion**

With improvement in awareness towards AILD and advancements in modern immunodiagnostic technology, a growing number of patients attacked by AILD are detected, the coexistence of extrahepatic autoimmune disease (EHAID) increases as well, especially the most prevalence of autoimmune thyroid disease (AITD) [3, 4, 23]. We recorded a high frequency of AITD in AILD (34.9%), with AIH concomitant with AITD being the commonest, followed by AIH-PBC OS and PBC. Our data showed that thyroid disease was mainly manifest as Hashimoto's thyroiditis, which was in consonance with studies by Floreani A [24] and Crowe J P [25]. And diffuse thyroid damage was more prevalent. This is hitherto the first study to elaborate the immunological relationship between AILD and AITD. TGAb and TPOAb are mainly IgG, TGAb in HT patients are predominantly IgG1, IgG2 and IgG4 and TPOAb in HT patients are mostly IgG1 and IgG4 [26-28]. Kawashima ST et al [29] have reported that 25.5% of patients with HT had elevated serum IgG levels. Similarly, the levels of IgG and γ-globulin in AILD concomitant with AITD were higher than those in AILD alone, and IgG in the three subgroups of AILD patients with concurrent AITD was higher than those of patients without concurrent AITD as well. Further exploration of the correlation between IgG and thyroid antibodies revealed a positive
correlation. It is possible, therefore, that presence of AITD could increase serum levels of IgG. Meanwhile, some AILD patients with concurrent AITD had undergone or were undergoing antithyroid or immunosuppressive therapy. Related literature has established that anti-thyroid therapy reduces thyroid antibody titers [30], signifying that IgG may be higher before controlling thyroid disease. Whether there is cross-reactivity of antithyroid autoantibodies in the presence of autoreactive T cells or similar epithelial antigens in both the liver and the thyroid, remains unclear. And further studies on molecular biology are required to be undertaken. The findings of this research provided insights that it is noteworthy screening for thyroid antibodies when distinctly elevated IgG was detected in patients with AILD; especially in PBC individuals, once IgG was found to be elevated dramatically, not only AIH-PBC overlap but also closely monitoring of thyroid function should be considered. This study revealed that nuclear homogenization ANA positivity was more prevalent in AIH concomitant with AITD compared to AIH alone. However, the result may be limited by the retrospective and small sample sizes of this study, whereby considerable multicenter and prospective cohort is necessary to estimate the probability. No statistical significance in other autoantibodies was attained between AILD patients with and without AITD, indicating that the specificity of autoantibodies in thyroid diseases was not evident and the screening of AITD susceptible individuals in AILD merely by certain autoantibodies was inappropriate.

Our study observed that the TPOAb positivity was the highest in PBC patients with concurrent AITD compared with other AILD patients with concurrent AITD, which was in parallel with Nakamura H’s findings [31]. Nevertheless, further research remains to be carried out whether it can be identified as a serological clue to distinguish AIH from PBC when the diagnosis is equivocal. Consequently, we set about exploring the expression of TPO (a membrane-bound glycoprotein containing a heme prosthetic group) and cholangiocytes surface proteins to establish a probable interplay of molecular mechanism. Murillo Perez CF et al [32] demonstrated that PBC patients diagnosed in recent decades are older than patients diagnosed in earlier decades over a 44-year follow-up. The PBC patients with concurrent AITD in our study were shown to be clustered in elderly subjects, which was in accord with that of Tojo J et al [33] who observed that PBC concomitant with CREST syndrome was older than that of PBC alone.
There may be two possible hypotheses. Firstly, autoimmune diseases presented occult progression, leading to an older age at presentation. Secondly, AILD and AITD were detected by accident when patients see their physician to undergo routine testing of liver and thyroid function, which occurs more frequently in older individuals. It seems that closely monitoring thyroid function is indispensable in the elderly PBC patients. However, Floreani A et al [34] did not observe an age difference between PBC patients with and without EHAID. Therefore, whether the difference exists is yet to be further confirmed by a comprehensive study.

Interestingly, our data showed that AITD more frequently coincided with AILD’s onset or occurred years after the diagnosis of AILD, which was conflict with Guan-Wee Wong’s [6] findings that EHAID predated AIH diagnosis. Actually, controversy still exists on the above results. Firstly, Thyroid abnormality was unveiled by accident during active stages of hepatitis, which was ignored or missed in previous clinical practice. Secondly, Patients, prior to AILD, who have suffered from thyroid disease and have accepted antithyroid therapy, whereas the liver function was not systematically screened then. After all, AILD tended to be asymptomatic at presentation. Lastly, it’s well-recognized that patients with autoimmune disease are prone to involve multiple organs, liver and thyroid might be affected simultaneously or successively. As a consequence, an uncertain sequence still exists in AILD and AITD. Meanwhile, the selection bias cannot be avoided, opinions on the onset time of disease vary from hepatologists to endocrinologists. Hence, it is of vital importance to strengthen the consultation between hepatologist and endocrinologist and promote the development of the MDT diagnosis and treatment model.

Conclusions
In summary, AITD was found to be the most prevalent concurrent autoimmune disease in AILD patients with concurrent EHAID. It seems reasonable to recommend routine screening for autoimmune thyroid disease in patients with AILD when IgG and γ-globulin were significantly elevated.

Abbreviations
EHAID: extrahepatic autoimmune disease; AILD: autoimmune liver disease; AITD: autoimmune thyroid
disease; HT: Hashimoto's thyroiditis; GD: Graves' disease; AIH-PBC OS: autoimmune hepatitis-primary biliary cholangitis overlap syndrome; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamyl transferase; ALP: alkaline phosphatase; IgG: immunoglobulin G; IgM: immunoglobulin M; γ-globulin: gamma globulin; ANA: antinuclear antibody; AMA: anti-mitochondrial antibody; AMA-M2: anti-mitochondrial antibody M2; TGAb: thyroglobulin antibody; TPOAb: thyroid peroxidase antibody.

Declarations

Acknowledgments

I would like to express my sincere thanks to my colleagues and teachers for their enlightenment and instruction, all the study subjects for participating in this study and the medical staffs at Tianjin Second People’s Hospital for their support and assistance with data collection.

Funding

This research received no specific grant from any funding agency.

Availability of data and materials

All data and analysis results are included in this article. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author contributions

Jia Li and Qingmin Zeng conceived and designed the study; Jia Li, Min Gao, Chunyan Wang supervised the study; Qingmin Zeng, Chunhua Tu, Ping Han collected data; Qingmin Zeng, Xu Han, Chen Chen, Lili Zhao analyzed data statistically; Qingmin Zeng wrote the manuscript; Jia Li, Min Gao, Chunyan Wang and Qingmin Zeng revised the manuscript. All authors reviewed the results and approved the final version of the manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Tianjin Second People’s Hospital. Written informed consent was obtained from all study participants.

Consent for publication

Not applicable.
**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Floreani A, Franceschet I, Cazzagon N, Spinazze A, Buja A, Furlan P, Baldo V, Gershwin ME. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2-3):192-7.

2. Chalifoux SL, Konyn PG, Choi G, Saab S. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut Liver. 2017;11(6):771-780.

3. Wong GW, Heneghan MA. Association of Extrahepatic Manifestations with Autoimmune Hepatitis. Dig Dis. 2015;33 Suppl 2:25-35.

4. Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Worns M, Lohse AW, Galle PR, Kanzler S. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44(3):208-13.

5. Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol. 2015;27(10):1175-9.

6. Wong GW, Yeong T, Lawrence D, Yeoman AD, Verma S, Heneghan MA. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver Int. 2017;37(3):449-457.

7. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335(2):99-107.

8. Koyamada R, Higuchi T, Kitada A, Nakagawa T, Ikeya T, Okada S, Fujita Y. Association of Primary Biliary Cirrhosis-autoimmune Hepatitis Overlap Syndrome with Immune Thrombocytopenia and Graves' Disease. Intern Med. 2015;54(16):2013-6.

9. Pamfil C, Candrea E, Berki E, Popov HI, Radu PI, Rednic S. Primary biliary cirrhosis-
autoimmune hepatitis overlap syndrome associated with dermatomyositis, autoimmune thyroiditis and antiphospholipid syndrome. J Gastrointestin Liver Dis. 2015;24(1):101-4.

10. Aksoy EK, Yilmaz B, Koklu S. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome developed in a patient with vitiligo and Hashimoto thyroiditis. Eur J Gastroenterol Hepatol. 2013;25(1):121-2.

11. Efe C, Wahlin S, Ozaslan E, Berlot AH, Purnak T, Muratori L, Quarneti C, Yuksel O, Thiefin G, Muratori P. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol. 2012;24(5):531-4.

12. Du YQ, Liu DP. Clinical comparative analysis of 29 cases of autoimmune hepatitis concomitant with other autoimmune diseases. Chin J Postgrad Med. 2012(28):50-52.

13. Ozaslan E. Autoimmune hepatitis-autoimmune cholangitis overlap syndrome and autoimmune thyroiditis in a patient with celiac disease. Eur J Gastroenterol Hepatol. 2009;21(6):716-8.

14. Nobili V, Liaskos C, Luigi G, Guidi R, Francalanci P, Marcellini M. Autoimmune thyroiditis associated with autoimmune hepatitis. Thyroid. 2005;15(10):1193-5.

15. Arvola T, Mustalahti K, Saha MT, Vehmanen P, Partanen J, Ashorn M. Celiac disease, thyrotoxicosis, and autoimmune hepatitis in a child. J Pediatr Gastroenterol Nutr. 2002;35(1):90-2.

16. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929-38.

17. EASL Clinical Practice Guidelines: The diagnosis and management of patients with
primary biliary cholangitis. J Hepatol. 2017;67(1):145-172.

18. Consensus on the diagnosis and management of primary sclerosing cholangitis(2015). J Clin Hepatol. 2016(01):23-31.

19. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-67.

20. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.

21. Chinese Society of Endocrinology. Guidelines for the diagnosis and treatment of adult hypothyroidism. Chin J Endocrinol Metab. 2017,33(2):167-180.

22. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19(12):1409-17.

23. Floreani A, De Martin S, Secchi MF, Cazzagon N. Extrahepatic autoimmunity in autoimmune liver disease. Eur J Intern Med. 2018.

24. Floreani A, Mangini C, Reig A, Franceschet I, Cazzagon N, Perini L, Caballeria L, Cocchio S, Baldo V, Pares A. Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. Am J Gastroenterol. 2017;112(1):114-119.

25. Crowe JP, Christensen E, Butler J, Wheeler P, Doniach D, Keenan J, Williams R. Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology. 1980;78(6):1437-41.

26. Gao Y, LM M, Xiu RJ. Progress in immunological pathogenesis of Hashimoto's thyroiditis. J Intern Med Concepts Pract. 2013(06):392-396.

27. Zhang H, Cui C. Serum IgG subtype and autoimmune thyroid disease. J Clin Intern
28. Xie LD, Gao Y, Li MR, Lu GZ, Guo XH. Distribution of immunoglobulin G subclasses of anti-thyroid peroxidase antibody in sera from patients with Hashimoto's thyroiditis with different thyroid functional status. Clin Exp Immunol. 2008;154(2):172-6.

29. Kawashima ST, Tagami T, Nakao K, Nanba K, Tamanaha T, Usui T, Naruse M, Minamiguchi S, Mori Y, Tsuji J et al. Serum levels of IgG and IgG4 in Hashimoto thyroiditis. Endocrine. 2014;45(2):236-43.

30. Smith TJ, Hegedus L. Graves' Disease. N Engl J Med. 2016;375(16):1552-1565.

31. Nakamura H, Usa T, Motomura M, Ichikawa T, Nakao K, Kawasaki E, Tanaka M, Ishikawa K, Eguchi K. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest. 2008;31(10):861-5.

32. Murillo PC, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology. 2018;67(5):1920-1930.

33. Tojo J, Ohira H, Suzuki T, Takeda I, Shoji I, Kojima T, Takagi T, Kuroda M, Miyata M, Nishimaki T et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res. 2002;22(3):187-195.

34. Floreani A, Franceschet I, Cazzagon N, Spinazze A, Buja A, Furlan P, Baldo V, Gershwin ME. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2-3):192-7.

Tables

Table 1  Frequency of EHAID in AILD patients
Table 2  Comparison of clinical features between AIH patients with and without AITD

|                          | AIH (n=77) | AIH with AITD (n=65) | P-value |
|--------------------------|------------|----------------------|---------|
| Male/Female              | 12/65      | 4/61                 | 1.0     |
| Age, year                | 54.36 ± 1.40 | 53.66 ± 1.20          | 0.7     |
| Family history of AID    | 5          | 8                    | 0.2     |
| ALT (IU/L)               | 36.0(182.5~710.0) | 378.0(171.0~566.5)  | 0.5     |
| AST (IU/L)               | 300.0(149.5~614.5) | 319.0(161.0~577.5)  | 0.6     |
| IgG (g/L)                | 17.5(14.9~19.9) | 21.7(17.6~29.1)      | < 0.0   |
| γ-globulin (%)           | 22.4(19.4~25.6) | 26.4(22.4~32.3)      | < 0.0   |
| ANA                      | cytoplasmic granules 26 | 17       | 0.3     |
|                         | nuclear granules 33 | 28       | 1.0     |
|                         | nuclear homogenous 9 | 18       | 0.0     |
|                         | centromere 1       | 2        | 0.5     |
|                         | Anti-dsDNA 11      | 15       | 0.1     |
|                         | Cirrhosis 23       | 21       | 0.8     |

Data were shown as mean ± SD and/or median (range).

AIH, autoimmune hepatitis; AITD, autoimmune thyroid disease. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; ALP, alkaline phosphatase; IgG, immunoglobulin G; IgM, immunoglobulin M; γ-globulin, gamma globulin; ANA, antinuclear antibody; AMA, anti-mitochondrial antibody; AMA-M2, anti-mitochondrial antibody M2. *P<0.05.

Table 3  Comparison of clinical features between PBC patients with and without AITD
Table 4 Comparison of clinical features between AIH-PBC OS patients with and without AITD

|                         | AIH-PBC OS(n=26) | AIH-PBC OS(n=17) +AITD | P-value |
|-------------------------|------------------|------------------------|---------|
| Male/Female             | 3/23             | 1/16                   | 0.642   |
| Age, year               | 57.38±1.23       | 58.41±3.16             | 0.731   |
| Family history of AID   | 2                | 3                      | 0.369   |
| ALT(IU/L)               | 122.0(51.3~300.8)| 71.0(28.5~232.5)       | 0.243   |
| AST(IU/L)               | 147.0(71.5~393.8)| 104.0(36.5~192.0)      | 0.117   |
| GGT(IU/L)               | 245.5(116.8~523.8)| 231.0(143.55~433.0)   | 0.619   |
| ALP(IU/L)               | 197.0(136.3~474.3)| 187.0(129.0~252.0)     | 0.315   |
| IgG(g/L)                | 18.6(15.7~21.9)  | 24.3(17.3~26.1)        | 0.035*  |
| IgM(g/L)                | 2.2(1.5~4.4)     | 3.7(2.1~5.3)           | 0.129   |
| γ-globulin(%)           | 25.8(19.4~29.0)  | 29.6(22.2~36.2)        | 0.081   |
| ANA                     |                  |                        |         |
| cytoplasmic granules    | 17               | 12                     | 1.000   |
| nuclear granules        | 7                | 4                      | 1.000   |
| centromere              | 4                | 2                      | 1.000   |
| AMA                     | 15               | 11                     | 0.755   |
| AMA-M2                  | 11               | 11                     | 0.215   |
| Cirrhosis               | 11               | 8                      | 1.000   |

Data were shown as mean ± SD and/or median (range).

AIH-PBC OS, autoimmune hepatitis-primary biliary cholangitis overlap syndrome; AITD, autoimmune thyroid disease. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; ALP, alkaline phosphatase; IgG, immunoglobulin G; IgM, immunoglobulin M; γ-globulin, gamma globulin; ANA, antinuclear antibody; AMA, anti-mitochondrial antibody.

Data were shown as mean ± SD and/or median (range).
antibody; AMA-M2, anti-mitochondrial antibody M2. *P<0.05.

Table 5 Comparison of immunological indicators between AILD patients with and without AITD

|                          | AILD(n=211) | AILD+AITD(n=113) | P-value |
|--------------------------|-------------|------------------|---------|
| Family history of AID    | 12          | 13               | 0.080   |
| EHAID                    | 32          | 24               | 0.170   |
| IgG(g/L)                 | 16.3(13.5~19.5) | 21.5(17.5~26.1) | <0.0001*|
| γ-globulin(%)            | 21.9(18.9~26.4) | 27.1(21.9~31.8) | <0.0001*|
| ANA                      |             |                  |         |
| cytoplasmic granules     | 106         | 46               | 0.104   |
| nuclear granules         | 53          | 34               | 0.359   |
| centromere               | 23          | 10               | 0.701   |

Data were shown as mean ± SD and/or median (range).

AILD, autoimmune liver disease; AITD, autoimmune thyroid disease; AID, autoimmune disease; EHAID, extrahepatic autoimmune disease. IgG, immunoglobulin G; γ-globulin, gamma globulin; ANA, antinuclear antibody. *P<0.05.

Table 6 Correlation between IgG and thyroid antibodies in AILD with concurrent AITD

| Thyroid antibody | r-value | P-value |
|------------------|---------|---------|
| TGAb(IU/mL)      | 0.396   | <0.0001*|
| TPOAb(IU/mL)     | 0.322   | 0.002*  |

AILD, autoimmune liver disease; AITD, autoimmune thyroid disease; TGAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody.*P<0.05.

Table 7 Thyroid manifestation in AILD with concurrent AITD

|                | AIH, n=65 | PBC, n=31 | AIH-PBC OS,n=17 | P-value |
|----------------|-----------|-----------|-----------------|---------|
| AITD           |           |           |                 |         |
| HT             | 42        | 20        | 12              | 0.891   |
| GD             | 17        | 5         | 3               | 0.438   |
| Other          | 6         | 6         | 2               | 0.371   |
| Thyroid antibody positivity |           |           |                 |         |
| TGAb           | 45        | 20        | 13              | 0.717   |
| TPOAb          | 39        | 26        | 9               | 0.035*  |
| TSH >4.20 ulU/mL | 27       | 10        | 10              | 0.203   |
| TSH <0.27 ulU/mL | 4        | 2         | 1               | 1.000   |
| Ultrasounds    |           |           |                 |         |
| Nodule         | 14        | 4         | 2               | 0.538   |
| Diffuse lesion | 32        | 15        | 13              | 0.125   |
| Time of onset of AITD |           |           |                 |         |
| Previous       | 7         | 5         | 2               | 0.788   |
| Posterior or simultaneous | 58       | 26        | 15              | 0.788   |
AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; AIH-PBC OS, autoimmune hepatitis-primary biliary cholangitis overlap syndrome; AILD, autoimmune liver disease; AITD, autoimmune thyroid disease; HT, Hashimoto's thyroiditis; GD, Graves' disease; TGAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody; TSH, thyroid stimulating hormone. *P<0.05.

Figures

Figure 1

Frequency of AITD in AILD patients. AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; AIH-PBC OS, autoimmune hepatitis-primary biliary cholangitis overlap syndrome; AITD, autoimmune thyroid disease.